First U.S. patient initiated in pivotal multi-center study for U.S. approval of the UNEEG EpiSight™ solution: a disruptive technology that may advance biomarker-based therapy for people with epilepsy

UNEEG medical, a company pioneering technologies that collect, monitor, and analyze brain activity, to improve diagnostics and treatment within epilepsy, announce initiation of the first U.S. patient in the U.S. pivotal clinical evaluation of the company’s flagship program for ultra long-term electroencephalogram (EEG) recording.
The UNEEG EpiSight solution has been available in the European Union since 2019, and the pivotal U.S. study will further expand the in-use validation ongoing at major epilepsy hospitals in Europe.

Read the press release here